Navigation Links
Pharmacyclics Reports Financial Results for Fiscal 2010 and for Fourth Quarter 2010
Date:9/13/2010

ign safety profile in line with our oral presentation at ASCO. As of August 31, 2010 we have completed enrollment of an additional cohort of 10 patients using a fixed, continuous dosing of 560 mg daily. Additionally, the National Cancer Institute (NCI) has dosed the first of 10 pre-typed ABC DLBCL patients. The company has submitted an abstract to the 2010 ASH annual meeting that describes the responses and the duration in all of the CLL/SLL patients dosed to date and we cannot disclose any information contained in the abstract prior to the meeting held in December.
  • Over the last 3 months the company held multiple advisory boards in the US and EU with experts in the field of lymphoma and CLL to obtain feedback to our clinical development plan. We now announce that the company is planning multiple Phase II trials in select B-cell derived malignancies (Mantle Cell in Velcade failure and Velcade naive patients, DLBCL in R-CHOP and transplant failures and CLL combination-safety trials with Bendamustine-Rituxan and Ofatumumab and other investigator initiated trials). Timelines for reportable events and regulatory interactions from these planned Phase II trials will be communicated after the ASH meeting in December.
  • A second Bruton's Tyrosine Kinase (Btk) Inhibitor, PCI-45292, is being developed for autoimmune disease; we are on track to complete IND-enabling preclinical safety studies. The company is planning to file an IND by the end of the second quarter of calendar 2011 with this molecule.
  • Factor VIIa Inhibitor, PCI-27483, is a potent and highly selective small molecule inhibitor of coagulation Factor VIIa.  Factor VIIa is best known for its role in triggering the extrinsic pathway of blood coagulation following contact and complex formation with the cell surface glycoprotein Tissue Factor.  Tissue Factor is over-expressed in pancreatic, gastric, lung, breast, colon and many other cancers of epithelial origin. FVIIa In
    '/>"/>

  • SOURCE Pharmacyclics
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

    Related medicine technology :

    1. Pharmacyclics Announces Data and Publication Characterizing Highly-Selective HDAC Inhibitor
    2. Pharmacyclics Announces Preclinical Results Supporting Development of Its Novel Btk Inhibitor in Immune Mediated Diseases
    3. Pharmacyclics Reports Multiple Presentations at AACR on Its HDAC and Selective HDAC Inhibitors
    4. Pharmacyclics Novel Factor VIIa Inhibitor Demonstrates Potential Inhibition of Tumor Growth in Multiple Types of Cancer
    5. Pharmacyclics Novel Btk Inhibitor Shows Efficacy in Preclinical Models of Rheumatoid Arthritis and Lymphoma
    6. Pharmacyclics Announces Completion of Phase 1 Clinical Trial of Factor VIIa Inhibitor PCI-27483
    7. Pharmacyclics, Inc. Announces Closing of a Private Financing With the Principals of Pacific Biopharma Group, Ltd.
    8. Pharmacyclics Initiates Phase 1 Clinical Trial of Novel Oral Btk Inhibitor for Refractory B-cell Non-Hodgkins Lymphoma
    9. Pharmacyclics announces Global Strategic Alliance with Les Laboratoires Servier
    10. Pharmacyclics to Present at Merriman Curhan Fords Investor Summit 2009
    11. Pharmacyclics Announces Poster Presentations and Clinical Update at the 51st Annual Meeting of the American Society of Hematology
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:8/21/2014)... PHILADELPHIA , Aug. 21, 2014  ACI ... platform for independent Data Monitoring Committees. ... to 30 percent over industry standard costs and ... an industry leader in committee services. ... member recruitment and contracting, charter development, statistical programming ...
    (Date:8/21/2014)... PARK, N.J. , Aug. 21, 2014 /PRNewswire/ ... pharmacy group purchasing organization (GPO), is pleased to ... to collaborate on a host of innovative specialty ... help Aurora deliver enhanced therapy management services to ... Management (OTM) system. Aurora will use ...
    (Date:8/21/2014)... 21, 2014  The board of directors of VirtualScopics, ... of clinical trial imaging solutions, today announced that ... officer, effective immediately.  Mr. Groff has held the role ... joined VirtualScopics in January 2006 as an accounting manager ... "When the board of VirtualScopics asked Jim to ...
    Breaking Medicine Technology:ACI Clinical: Innovation and Savings in Data Safety Monitoring Committees 2Aurora Health Care Partners with Armada Health Care to Deliver Added Pharmacy Capabilities to Specialty Patients 2Aurora Health Care Partners with Armada Health Care to Deliver Added Pharmacy Capabilities to Specialty Patients 3VirtualScopics, Inc. Names James Groff Chief Financial Officer 2VirtualScopics, Inc. Names James Groff Chief Financial Officer 3VirtualScopics, Inc. Names James Groff Chief Financial Officer 4
    ... BILLERICA, Mass., Sept. 15 HydroCision Inc. ( ... announced today the purchase of the majority of ... capital firms Volcano Capital, Bioventures, and Omega Funds. ... SpineJet®, whose innovative Fluidjet surgical technology allows discectomy ...
    ... VentiRx Pharmaceuticals, Inc., a biopharmaceutical company focused on the ... the treatment of cancer, respiratory and inflammatory diseases, announced ... FierceBiotech "Fierce 15" list, designating it as one of ... industry. Every year, FierceBiotech evaluates hundreds of private companies, ...
    Cached Medicine Technology:HydroCision Announces New Investment to Accelerate Growth of Novel Fluidjet Technology for Minimally Invasive Spine Surgery 2FierceBiotech Names VentiRx Pharmaceuticals as One of the 'Fierce 15' Biotech Companies of 2010 2
    (Date:8/21/2014)... 21, 2014 Today, Zane Benefits, the ... the premium tax credits in 2015. , According to ... part of the Affordable Care Act (ACA), premium tax ... individual health insurance through the Health Insurance Marketplaces. , ... and the amount of the tax credits, updated for ...
    (Date:8/21/2014)... MI (PRWEB) August 21, 2014 An ... informing a taxpayer that their federal tax payment is ... domain appears to come from the IRS, “tax@irs.gov”, it’s ... to provide personal and financial information. , While similar ... now, an uptick in phishing activity is occurring right ...
    (Date:8/21/2014)... heart-lung support technology, the University of Michigan,s Transplant Center ... and pancreases available for transplant by about 20 percent. ... Transplantation and detail the impact of more than ... to improve the quality and viability of organs donated ... limited by the number of donated organs available, so ...
    (Date:8/21/2014)... to exercise is a challenge. Thankfully, there are Zombies chasing ... of more than 31,000 health and fitness apps on the ... that use games to increase physical activity. , Gamification is ... to cash in to help people get fit. Whether or ... seen. , "It,s just been assumed that gamified apps will ...
    (Date:8/21/2014)... (PRWEB) August 21, 2014 Pulmonary ... with an Education Forum for PH patients and ... Who:    The Pulmonary Hypertension Association – the ... find ways to prevent and cure pulmonary hypertension ... affects the functioning of the heart and can ...
    Breaking Medicine News(10 mins):Health News:Beware Of Phony “Tax Payment Rejected” IRS Emails 2Health News:Extracorporeal support can significantly increase number of organs for transplant 2Health News:Playing hunger games: Are gamified health apps putting odds in your favor? 2Health News:Pulmonary Hypertension Association Goes On the Road to Houston With an Education Forum for PH Patients and Families to Help Fight Rare Lung Disease 2Health News:Pulmonary Hypertension Association Goes On the Road to Houston With an Education Forum for PH Patients and Families to Help Fight Rare Lung Disease 3
    ... , BETHEL, Conn., Dec. 4 MedClean Technologies, Inc. ... a preferred stock purchase agreement with Socius Capital Group, LLC, a ... Capital Group, LLC. Pursuant to the Purchase Agreement, MedClean will receive ... to sell up to 750 shares of its Series C Preferred ...
    ... , UNION, N.J., Dec. 4 ... its specialty anatomic pathology services with the launch of ... company,s expansion from a regional laboratory to a leading ... full range of specialties including gastroenterology, urology and now ...
    ... , , OKLAHOMA CITY, Dec. 4 ... for the first quarter ended September 30, 2009, a 24% decrease ... income for the quarter were $133,681 and $80,402, respectively, each a ... impacted by a decrease in pharmacy sector sales. This trend ...
    ... , SEATTLE, Dec. 4 The National Cancer Institute ... Research Center to become the nation,s sole operator of its Cancer ... jobs at the Hutchinson Center - nearly tripling the size of ... operational, which is scheduled for March 15, 2010. The Seattle CIS ...
    ... Medicine (BUSM) researchers at the Slone Epidemiology Center found that ... reduced incidence of uterine leiomyomata (fibroids). This report, based on ... of the American Journal of Epidemiology . Uterine ... to three times more common among black women than white ...
    ... ... initiative to establish standards for language access in healthcare organizations. , ... Hudson, OH (PRWEB) ... solutions, and patient education materials for healthcare institutions, understands the importance of effective ...
    Cached Medicine News:Health News:MedClean Technologies Enters Into Preferred Stock Agreement of Up to $7.5 Million 2Health News:MedClean Technologies Enters Into Preferred Stock Agreement of Up to $7.5 Million 3Health News:PLUS Diagnostics Launches Hematology/Oncology Diagnostic Services 2Health News:PLUS Diagnostics Launches Hematology/Oncology Diagnostic Services 3Health News:PD-Rx Pharmaceuticals, Inc. Reports 1st Quarter Earnings 2Health News:Hutchinson Center Wins $55.4 Million Contract to Become Sole Operator of the NCI Cancer Information Service 2Health News:Researchers find increased dairy intake reduces risk of uterine fibroids in black women 2Health News:Lexi-Comp Focused on Improving Patient Communication in Healthcare Institutions Treating Diverse Patient Populations 2Health News:Lexi-Comp Focused on Improving Patient Communication in Healthcare Institutions Treating Diverse Patient Populations 3
    Blunt tipped forceps with tungsten carbide treated jaws for enhanced gripping and removal of large sized foreign bodies....
    Blunt tipped forceps with entire interior surface of tip serrated. For general purpose membrane grasping (coarse membranes)....
    The Tano Asymmetrical Microforceps features an offset tip which allows optimal visualization along the entire tip length. Versatile tip design targets ILM, fine epiretinal membranes and diabetic or P...
    Microforceps : Eckardt End & Side Gripping Forceps...
    Medicine Products: